Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY

INTERPACE BIOSCIENCES, INC.

2025-Q3 EPS reported $0.07 revenue$29,504,000

Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M
Thyroid test volume grew 12% year-over-year to record levels; thyroid revenue $8.8M, up 22%
Cash collections $10.0M in Q3; days sales outstanding reduced 22%
Income from continuing operations $1.0M; adjusted EBITDA $1.3M
Company completed transition to thyroid-only diagnostics; additional debt principal payments made

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.